

Innovation all for the patients



Roche A member of the Roche group

## Maruho Announces Launch of Mitchga Subcutaneous Injection 30mg Vials in Japan

TOKYO, June 11, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Maruho Co., Ltd.](#) (hereafter, Maruho) issued a press release today, regarding the launch of Mitchga<sup>®</sup> Subcutaneous Injection 30mg Vials (Japanese Accepted Name (JAN): nemolizumab (Genetical Recombination)) in Japan for the treatment of the following diseases only when existing treatment is insufficiently effective: pruritus associated with atopic dermatitis (children aged  $\geq 6$  and  $< 13$  years) and prurigo nodularis (adults and children aged  $\geq 13$  years). Mitchga was originated from Chugai, and has been licensed-out to Maruho in Japan.

Please refer to the link below for details of the press release:

Maruho Launches "Mitchga<sup>®</sup> Subcutaneous Injection 30mg Vials", an Antibody Treatment for Pruritus Associated with Atopic Dermatitis (Pediatric) and Prurigo Nodularis in Japan

<https://www.maruho.co.jp/english/information/20240611.html>

###